Lu-ABY-271 not checked

Affibody

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Breast Cancer, HER2 + Breast Cancer
Main trialPhase 1
“This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \[177Lu\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.”In the company’s words, NCT07081555 on ClinicalTrials.gov

Other drugs for Metastatic Breast Cancer

All 397 drugs for Metastatic Breast Cancer

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 1 Jun 2027 A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Lu-ABY-271

Following is part of Solo: you see every change to Lu-ABY-271 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in